Evoke Pharma Inc 4
4 · Evoke Pharma Inc · Filed Oct 2, 2013
Insider Transaction Report
Form 4
Evoke Pharma IncEVOK
GLENN SCOTT L
Director
Transactions
- Conversion
Common Stock
2013-09-30+15,605→ 15,605 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2013-09-30−78,027→ 0 total(indirect: See footnote)→ Common Stock (15,605 underlying)
Holdings
- 25,250(indirect: See footnote)
Common Stock
Footnotes (3)
- [F1]The Issuer's Series A Preferred Stock (the "Preferred Stock") has no expiration date. The outstanding shares of Preferred Stock automatically converted into shares of Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering at a conversion ratio of one share of Common Stock for every five shares of Preferred Stock, rounded down to the nearest whole number, for no additional consideration.
- [F2]The shares are held by Windamere III, LLC, of which Mr. Glenn is the Managing Member.
- [F3]The shares are held by Glenn Holdings, L.P., of which Mr. Glenn is the General Partner.